How we got here, where we are going and being a cog in something turning.
about
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesiclesNanoinformatics: emerging databases and available toolsEGF receptor-targeted nanocarriers for enhanced cancer treatmentPolymeric nanoparticles for targeted treatment in oncology: current insightsNanoinformatics: a new area of research in nanomedicineDrug delivery nanoparticles in skin cancersInnate Immune Responses to Nanoparticle Exposure in the LungToxicological considerations when creating nanoparticle-based drugs and drug delivery systemsNanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosisBiosensors: the new wave in cancer diagnosis.Nanomedicine: promising tiny machine for the healthcare in future-a review.Optically guided controlled release from liposomes with tunable plasmonic nanobubbles.Plasmonic nanobubbles as tunable cellular probes for cancer theranosticsCaught in the act: revealing the metastatic process by live imaging.Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.Targeted drug delivery in pancreatic cancerNanofunctionalized zirconia and barium sulfate particles as bone cement additives.Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications.Enabling individualized therapy through nanotechnologySelective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubesViral and nonviral delivery systems for gene deliveryA review on composite liposomal technologies for specialized drug delivery.Differential stability of lead sulfide nanoparticles influences biological responses in embryonic zebrafish.Synthesis and evaluation of perfluorooctylbromide nanoparticles modified with a folate receptor for targeting ovarian cancer: in vitro and in vivo experiments.Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.Nanotechnology-based approaches in anticancer researchLow molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxelDNA nanotechnology: a future perspective.Design Strategies for Fluorescent Biodegradable Polymeric Biomaterials.Lipid-based nanoparticles in cancer diagnosis and therapy.Small-molecule delivery by nanoparticles for anticancer therapyFourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier.Cationic nanoparticles for cancer therapy.A comparison of peptide and folate receptor targeting of cancer cells: from single agent to nanoparticle.Advances in cancer therapy through the use of carbon nanotube-mediated targeted hyperthermiaSingle-chain polymer nanoparticles.Aptamer-dendrimer bioconjugate: a nanotool for therapeutics, diagnosis, and imaging.Biophysical evaluation of radiofrequency electromagnetic field effects on male reproductive pattern.Targeting and delivery of platinum-based anticancer drugs.
P2860
Q24599399-188FB8BF-EC3E-4476-83A6-D37FAFD6E4E6Q26801293-84AECFAF-E1F3-4E1D-82EB-B21F5AC21906Q27008517-C40782FB-42A5-4A1E-BD22-F811E0E72CE5Q27013001-F328E6DE-2A0D-4A90-8735-C806FB92A07BQ28087243-D0277BA1-791E-4D85-A7C0-894E4C87CA06Q28387114-D9DECCFD-FFD7-490D-9670-8C046F2B6AB1Q28390405-F464891B-8208-4652-A56F-C11072E68D40Q28394494-B8016C53-ED37-4936-B625-4DC6CBB50EF5Q28395046-54D41E38-882B-40A8-8936-0575B85B0C11Q28395895-665AB61B-3589-47EB-8E1E-2C6C46EF5BC5Q30447534-C3F02314-4A6F-457D-A34A-35DD9F4EE0BAQ30471659-371DF947-469E-42D4-B9E6-6C53000E7E3AQ30475318-33E14201-82B8-44F7-9CAB-D03E1EBDDFC4Q30476207-7C683F54-EC7C-4054-B51E-62A135F77776Q30539138-D3DBAC83-AC09-4B6D-873A-EBF89D9503D9Q30997567-E91E998A-AEBD-49E7-A1B3-D73ED3EFD090Q33625651-E536C336-800A-4473-9928-AB54E87B3209Q33644865-801886FD-8108-4280-B9A5-2BDEF8F541B0Q33740696-7A71574C-572C-432E-A46A-F52BAD5FA725Q33917755-6ADC7B6F-8FA2-483C-B365-673C58DDDA40Q33947931-6FF20A7B-AED0-4BD8-AE05-5C912F8A4DB4Q34315475-3AE9A8E6-867C-459B-A16C-F1D34F8CB782Q34730109-794FD6E4-3414-4003-B4D7-331D6DC2A57CQ35140794-6C7E2280-9677-4051-AFD5-FAE9B511EDE9Q35756395-5555E1EE-99EF-4E2D-A8DB-DA4F7BE15E1AQ36010344-6AD07DD2-9FEB-4047-A34B-8AF2AC9720A3Q36168983-BD23B6D6-D20E-46B1-AE91-4DDA549796F3Q36414534-C9F786A1-A813-47CB-9F06-47C931EE9149Q36690125-96D13162-0411-43AF-8B12-93740927A909Q36864841-1AB43ACC-80A1-4C66-AE97-D9BAC3973B99Q37052002-10100FA4-A114-4741-978E-DD5E154B7704Q37059874-F5FFC1E9-B84F-4B9A-BA9C-EA8C2392D537Q37378143-4AA9C946-F28A-4800-88FB-2D022FF4FDC7Q37743515-FDB0B1C2-2FF3-41D1-B5AD-29D46021871BQ37838443-24222A5F-188C-40FA-8D4D-C2E64D27D5F3Q37929553-57AB8B76-0861-48A2-87E2-94B5CB130DDFQ37947950-91A9EBBD-0ACC-4307-A43D-809EC8016F3BQ38035033-0411785E-7E76-4670-B2D2-EC05D8C75B8FQ38038485-0AE8795E-CA8B-439F-B57E-2AB37469F539Q38050063-2E82F584-8B57-44B7-A35C-1421266F7A21
P2860
How we got here, where we are going and being a cog in something turning.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How we got here, where we are going and being a cog in something turning.
@en
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.
@nl
type
label
How we got here, where we are going and being a cog in something turning.
@en
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.
@nl
prefLabel
How we got here, where we are going and being a cog in something turning.
@en
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.
@nl
P2860
P31
P921
P356
P1476
How we got here, where we are going and being a cog in something turning.
@en
P2093
Charles R Martin
P2860
P356
10.2217/17435889.4.1.1
P407
P577
2009-01-01T00:00:00Z
2009-04-01T00:00:00Z